LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

Search

United Therapeutics Corp

Chiusa

SettoreSettore sanitario

400.72 5.52

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

396.58

Massimo

400.72

Metriche Chiave

By Trading Economics

Entrata

-13M

310M

Vendite

4.2M

799M

P/E

Media del settore

15.794

35.733

EPS

6.63

Margine di Profitto

38.755

Dipendenti

1,305

EBITDA

54M

437M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+16.24% upside

Dividendi

By Dow Jones

Utili prossimi

29 ott 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

4.9B

18B

Apertura precedente

395.2

Chiusura precedente

400.72

Notizie sul Sentiment di mercato

By Acuity

32%

68%

98 / 371 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bullish Evidence

United Therapeutics Corp Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

7 ott 2024, 15:14 UTC

I principali Market Mover

Liquidia Shares Rise After Supreme Court Rejects United Therapeutics' Patent Appeal

28 gen 2025, 10:30 UTC

Notizie principali

Drug Companies Raise Prices on More Than 800 Drugs in January -- WSJ

Confronto tra pari

Modifica del prezzo

United Therapeutics Corp Previsione

Obiettivo di Prezzo

By TipRanks

16.24% in crescita

Previsioni per 12 mesi

Media 465.56 USD  16.24%

Alto 575 USD

Basso 295 USD

Basato su 12 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per United Therapeutics Corp - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

12 ratings

8

Acquista

4

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

292.345 / 309.245Supporto e resistenza

A breve termine

Weak Bullish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

98 / 371 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo United Therapeutics Corp

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
help-icon Live chat